Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) - Hsia, J; MacFadyen, J G; Monyak, J; Ridker, P M (J Am Coll Cardiol, 2011)